演題詳細

ポスター / Poster

ポスター 23 (Poster 23) :低悪性度B細胞リンパ腫:ベンダムスチン

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
瀧本 理修 (Rishu Takimoto):1
1:札幌医科大学医学部附属病院 腫瘍・血液内科
 
前へ戻る

Bendamustine therapy for relapsed/refractory B-cell lymphoma in single institution

演題番号 : PS-1-167

奥 英二郎 (Eijiro Oku):1、野原 正行 (Masayuki Nohara):1、籠手田 聡子 (Satoko Koteda):1、川口 城毅 (Kuniki Kawaguchi):1、野村 桂 (Kei Nomura):1、中村 剛之 (Takayuki Nakamura):1、武田 治美 (Harumi Takeda):1、森重 聡 (Satoshi Morishige):1、山口 真紀 (Maki Yamaguchi):1、関 律子 (Ritsuko Seki):1、毛利 文彦 (Fumihiko Mouri):1、大崎 浩一 (Koichi Osaki):1、今村 理恵 (Rie Imamura):1、橋口 道俊 (Michitoshi Hashiguchi):1、長藤 宏司 (Koji Nagafuji):1、岡村 孝 (Takashi Okamura):1

1:Dept. Hematology and Oncology Kurume Univ. Kurume, Japan

 

Background:We retrospectively evaluated the efficacy and safety of bendamustine in patients treated in our institute for relapsed/refractory B-cell lymphoma. Methods: Between August2010 and November 2012, 15 patients with indolent lymphoma, 4 patients with mantle cell lymphoma and 2 patients with diffuse large B cell lymphoma received bendamustine. The median age was 69 years (range, 38-81). Seven patients were male and 14 patients were female.The median number of previous chemotherapy regimens was 2 (range, 1-5). The treatment consisted of bendamustine90-120mg/m2 on 2 consecutive days every 3-4 weeks. Results: The median treatment cycle was 4-cycle(range, 1-6). The overall response was 71%(15/21, 8 CR, 7 PR). The major hematological adverse events of grade 3 to 4 were anemia 23%, neutropenia 90%, lymphopenia 90% and thrombocytopenia 38%. There were no deaths attributed to bendamustine treatment. Conclusion: Bendamustine is effective in patients with relapsed/refractory B-cell lymphoma.

前へ戻る